Aktienanalyse zu Pluri Inc (PLUR)PLURPluri Inc

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Pluri Inc is a good buy right now due to its recent positive developments and potential for growth. The stock is currently priced at $1.24, which is significantly below its 52-week high of $4.87, indicating room for recovery. The company has shown a 29.60% increase over the past 20 days, suggesting a positive trend. Additionally, the forward P/E ratio is 3.63, indicating potential undervaluation compared to future earnings expectations. The main risk is the high net income loss, which was -$5.5 million in the latest quarter, indicating ongoing financial challenges that need to be monitored closely.